Matches in Nanopublications for { ?s ?p "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP261929.RABg70dwPNV9T3q_cj1-n1eXz8CZWKtjzHOzhN9Qet_0k130_assertion description "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP261929.RABg70dwPNV9T3q_cj1-n1eXz8CZWKtjzHOzhN9Qet_0k130_provenance.
- assertion description "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1069443.RA6K9sgObh3pIvU6TlrWMSfIqlEOyHSZQ2JOoSDUk4Vu8130_assertion description "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1069443.RA6K9sgObh3pIvU6TlrWMSfIqlEOyHSZQ2JOoSDUk4Vu8130_provenance.
- NP1069441.RAFettJDlrvbjRBGrLDio7YGSe4bDSe7V1iL_xeYs6t-g130_assertion description "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1069441.RAFettJDlrvbjRBGrLDio7YGSe4bDSe7V1iL_xeYs6t-g130_provenance.
- NP1069444.RAGr5YvahGmCOIQJrp1Uqu9YoS8zyRb28jeIDUUyUZ7fU130_assertion description "[These preclinical data suggested that downregulation of Bcl-2 by RNAi in the gefitinib-resistant H1975 lung cancer cell line with T790M mutation enhanced the effects of gefitinib and may offer a novel therapeutic strategy for the treatment of NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1069444.RAGr5YvahGmCOIQJrp1Uqu9YoS8zyRb28jeIDUUyUZ7fU130_provenance.